DAX6.693-1,4%  Dow12.801-0,7%  Euro1,3200-0,7% 
ESt502.481-1,7%  Nas2.904-0,8%  Öl117,6-0,9% 
TDax769,9-0,4%  Nikkei8.947-0,6%  Gold1.721-0,5% 

OSI Pharmaceuticals Aktie [WKN: 873205 / ISIN: US6710401034]

Kurse + Charts + RealtimeNews + AnalysenFundamentalUnternehmenzugeh. WertpapiereAktion
Kurs + ChartChart (groß)News + AdhocBilanz/GuVTermineZertifikateDepot
Times + SalesChart-AnalyseAnalysenDividende/HVProfilOptionsscheineWatchlist
BörsenplätzeChartvergleichKursziele InsidertradesKnock-outsmyfinanzen
OrderbuchRealtime StuttgartRSS Feed im ForumFondsSenden
HistorischRealtime Push  IR-DatenAnleihen
handeln
Diese Aktie wird nicht mehr gehandelt

Hinweis

Auf dieser Seite finden Sie ALLE Nachrichten zur OSI Pharmaceuticals Inc.. Links ausgesuchte Top-Nachrichten, rechts weitere Meldungen.

Top-Nachrichten

DAX rettet leichtes Plus in Feierabend - Techwerte mit schwachem Wochenstart -- GM fährt in die Gewinnzone -- Euro nach 4-Jahres-Tief leicht stabilisiert -- TUI, VW, Coba, ATOSS, Prudential im Fokus
Erstes Griechenland-Geld fließt am Dienstag. KfW Bank setzt positive Geschäftsentwicklung fort. Empire State Manufacturing Index sinkt. HOCHTIEF mit solider Bilanz. Will Intel Infineons Handysparte? Amex an RBS-Sparte interessiert? Milliardenübernahme im Pharmabereich: Astellas kauft OSI. Europäischer Automarkt im April schwächer. Sybase: SAP verteidigt Milliardendeal. Heideldruck verspricht schwarze Zahlen. Beiersdorf mit optimistischem Umsatzziel. » mehr
Medizinaktien
Diagnose: Akuter Kaufzwang
In der Medizin- und Pharmabranche toben heiße Übernahmekämpfe. Wer auf die richtigen Aktien setzt, fährt schnell zweistellige Kursgewinne ein » mehr

Weitere Meldungen

25.05.10Astellas Pharma will Umsatz in China mittelfristig verdoppeln
17.05.10Wall Street Schluss: Indizes drehen ins Plus
17.05.10Wall Street Update: Indizes im Korrekturmodus
17.05.10Wall Street Eröffnung: Dow knapp behauptet, GM erzielt wieder Gewinn
17.05.10Börsen in Asien: Auf Talfahrt, NTT deutlich fester

ANZEIGE

17.05.10Astellas Pharma übernimmt OSI Pharmacueticals für 4 Mrd. Dollar
22.03.10OSI Pharmaceuticals Announces Details of Redemption of 3.25% Convertible Senior Subordinated Notes
19.03.10OSI Pharmaceuticals Announces That Tarceva® Received a Positive Opinion from Health Authorities in the European Union for First-Line Maintenance Use in Advanced Non-Small Cell Lung Cancer
16.03.10OSI Pharmaceuticals Comments on Astellas’ Slate of Director Nominees
15.03.10OSI Pharmaceuticals’ Board of Directors Unanimously Rejects Astellas’ Unsolicited Tender Offer
03.03.10Law Office of Brodsky & Smith, LLC Announces Investigation of OSI Pharmaceuticals, Inc.
02.03.10OSI Pharmaceuticals Board of Directors to Review Astellas’ Unsolicited Tender Offer
02.03.10Börsen in Asien: Teils deutliche Gewinne, Astellas im Blick
02.03.10Law Offices of Howard G. Smith Announces Investigation On Behalf of Shareholders of OSI Pharmaceuticals, Inc.
01.03.10Bernstein Liebhard LLP Announces Investigation on Behalf of Shareholders of OSI Pharmaceuticals
01.03.10Stull, Stull & Brody Announces Investigation on Behalf of Shareholders of OSI Pharmaceuticals, Inc.
01.03.10Börse Frankfurt Schluss: Satte Gewinne, Merck schluckt Millipore
01.03.10OSI Pharmaceuticals Confirms Receipt of Unsolicited Proposal From Astellas Pharma
01.03.10Astellas Pharma will OSI Pharmacueticals für 3,5 Mrd. Dollar kaufen
25.02.10OSI Pharmaceuticals to Present at the RBC Capital Markets Healthcare Conference on Tuesday, March 2, 2010
23.02.10OSI Pharmaceuticals, Inc. Announces Year End 2009 Financial Results
09.02.10OSI Pharmaceuticals to Announce Fourth Quarter and Year-End 2009 Financial Results on February 23, 2010
28.01.10Novella Clinical and OSI Pharmaceuticals Expand Clinical Services Agreement
15.01.10FDA Extends Review Period for Tarceva Application for First-Line Maintenance Use in Advanced Non-Small Cell Lung Cancer
12.01.10OSI Pharmaceuticals, Inc. Announces Fourth Quarter and 2009 Full Year Tarceva Sales at JP Morgan Healthcare Conference
06.01.10OSI Pharmaceuticals to Present at the 28th Annual JP Morgan Healthcare Conference on Tuesday, January 12, 2010
29.12.09U.S. Patent and Trademark Office Grants Reissued Patent Replacing OSI Pharmaceuticals’ Tarceva® Composition of Matter Patent
22.12.09OSI Pharmaceuticals Updates Preliminary Revenue & Re-affirms Adjusted Earnings Growth Rate Guidance for 2010
16.12.09OSI Pharmaceuticals Announces Conference Call on ODAC Review of Tarceva® for Use as First-line Maintenance Therapy in Advanced Non-Small Cell Lung Cancer
16.12.09FDA Advisory Committee Recommends Against Approving Tarceva for First-Line Maintenance Use in Advanced Non-Small Cell Lung Cancer
19.11.09OSI Pharmaceuticals to Webcast its R&D Analyst Day on Thursday, December 3rd
16.11.09OSI Pharmaceuticals Announces Tarceva to Be Reviewed by the FDA's Oncologic Drugs Advisory Committee for Use as a First-Line Maintenance Therapy in Advanced Non-Small Cell Lung Cancer
09.11.09OSI Pharmaceuticals to Present at the Lazard Capital Markets 6th Annual Healthcare Conference on Tuesday, November 17, 2009
27.10.09OSI Pharmaceuticals to Present at the Oppenheimer 20th Annual Healthcare Conference on Tuesday, November 3, 2009
21.10.09OSI Pharmaceuticals, Inc. Announces Third Quarter 2009 Financial Results
12.10.09OSI Pharmaceuticals to Announce Third Quarter 2009 Financial Results on October 21, 2009
17.09.09U.S. Patent and Trademark Office Issues a Notice of Allowance in OSI Pharmaceuticals’ Reissue Application on Tarceva® Composition of Matter Patent
08.09.09OSI Pharmaceuticals to Present at the Morgan Stanley Healthcare Conference on Tuesday, September 15, 2009
03.09.09OSI Pharmaceuticals Initiates Phase III Registration-Oriented Study for OSI-906 in Adrenocortical Carcinoma and Phase I/II Study in Ovarian Cancer
01.09.09OSI Pharmaceuticals to Present at The Thomas Weisel Partners Healthcare Conference on Wednesday, September 9, 2009